GW Pharmaceuticals Plc (GWPH) : The money flow is calculated as the dollar value of composite uptick trades minus the dollar value of downtick trades, which was negative (2.51 million) in GW Pharmaceuticals Plc (GWPH). On Wednesday, The value of composite uptick trades was $17.2 million, whereas, the value of composite downtick trades was $19.71 million and the ratio between the two was 0.87, indicating selling on strength. Traders involved in block trades booked profits in their holdings as seen in the transactions on downticks valued at $2.52 million. The negative money flow of ($2.52 million) shows selling on strength. GW Pharmaceuticals Plc (GWPH) gained $5.03 intraday at $129.94 and registrered 4.03% for the week.
Shares of GW Pharmaceuticals plc rose by 20.54% in the last five trading days and 61.36% for the last 4 weeks. GW Pharmaceuticals plc is up 39.62% in the last 3-month period. Year-to-Date the stock performance stands at 87.41%.
GW Pharmaceuticals Plc (GWPH) : Zacks Investment Research ranks GW Pharmaceuticals Plc (GWPH) as 1, which is a Strong Buy recommendation. 4 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. 1 other analysts are mildly bullish on the stock and favor a Buy. 1 more believe that the stock has more downside risks, hence they propose a Strong Sell. The average broker rating of 6 research analysts is 1.75, which indicates as a Buy.
GW Pharmaceuticals Plc (NASDAQ:GWPH): The stock opened at $125.54 and touched an intraday high of $130.24 on Wednesday. During the day, the stock corrected to an intraday low of $122.94, however, the bulls stepped in and pushed the price higher to close in the green at $130.14 with a gain of 4.19% for the day. The total traded volume for the day was 903,398. The stock had closed at $124.91 in the previous trading session.
GW Pharmaceuticals plc is a United Kingdom-based biopharmaceutical company. The Company is engaged developing a portfolio of cannabinoid medicines, including Sativex for the treatment of multiple sclerosis spasticity and cancer pain, and Epidiolex for the treatment of childhood epilepsy. The Company also engaged in developing cannabinoids, medicines containing controlled substances, as well as plant-based prescription pharmaceutical products. The Companys product, Sativex is approved in 27 countries and is used as a treatment for symptom improvement in patients with moderate to severe spasticity due to multiple sclerosis (MS). The Sativex is also in Phase III clinical development for the treatment of cancer pain, the indication for the United States market.